Compare GTES & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTES | COGT |
|---|---|---|
| Founded | 1911 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.9B |
| IPO Year | 2017 | 2018 |
| Metric | GTES | COGT |
|---|---|---|
| Price | $24.48 | $32.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $28.56 | ★ $36.21 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.73 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $7,871,000.00 |
| Revenue This Year | $5.83 | N/A |
| Revenue Next Year | $3.95 | $1,733.58 |
| P/E Ratio | $111.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.39 | $4.55 |
| 52 Week High | $28.47 | $43.73 |
| Indicator | GTES | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 30.56 |
| Support Level | $23.99 | $14.00 |
| Resistance Level | $26.29 | $37.69 |
| Average True Range (ATR) | 0.88 | 1.36 |
| MACD | -0.09 | -0.33 |
| Stochastic Oscillator | 19.65 | 0.59 |
Gates Industrial Corp PLC is a manufacturer of engineered power transmission and fluid power solutions. The company has two operating segments; Power Transmission and Fluid Power segments. The Power Transmission solutions convey power and control motion. It is used in applications in which belts, chains, cables, geared transmissions, or direct drives transfer power from an engine or motor to another part or system. The Fluid power solutions are used in applications in which hoses and rigid tubing assemblies either transfer power hydraulically or convey fluids, gases, or granular materials from one location to another. The company generates key revenue from the Power Transmission segment. Company operates in USA, United Kingdom, Luxembourg, EMEA, with majority revenue from USA.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.